Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 Future 3-5Y EPS without NRI Growth Rate is -40.84 as of Aug. 04, 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 400 Biotechnology companies, Puma Biotechnology ranks worse than 95% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate is -40.84.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Puma Biotechnology Future 3-5Y EPS without NRI Growth Rate Related Terms
PBYI vs EVMN, OCGN, EDIT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of -40.84 mean?
Puma Biotechnology (PBYI) has a Future 3-5Y EPS without NRI Growth Rate of -40.84 as of Aug. 04, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Puma Biotechnology and its competitors. According to the industry distribution chart, Puma Biotechnology ranks #380 out of 400 companies in the Biotechnology industry, placing it in the top 95%.
Is Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate too high?
Puma Biotechnology's current Future 3-5Y EPS without NRI Growth Rate is -40.84. Based on the distribution chart, Puma Biotechnology ranks #380 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Future 3-5Y EPS without NRI Growth Rate compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #380 out of 400 companies for Future 3-5Y EPS without NRI Growth Rate. This places Puma Biotechnology in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 21.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Biotechnology company?
The median Future 3-5Y EPS without NRI Growth Rate among Biotechnology companies is 21.66, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Puma Biotechnology and its competitors. For the Biotechnology industry, the median Future 3-5Y EPS without NRI Growth Rate is 21.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Future 3-5Y EPS without NRI Growth Rate is -40.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is -40.84. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Future 3-5Y EPS without NRI Growth Rate is -40.84 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Future 3-5Y EPS without NRI Growth Rate: -40.84
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
